MiR‑506 inhibits cell proliferation, invasion, migration and epithelial‑to‑mesenchymal transition through targeting RWDD4 in human bladder cancer

Hou,Yi

doi:10.3892/ol.2018.9594

MiR‑506 inhibits cell proliferation, invasion, migration and epithelial‑to‑mesenchymal transition through targeting RWDD4 in human bladder cancer

Authors:
- Yi Hou
View Affiliations

Affiliations: Department of Urology, The Fourth People's Hospital of Shenyang, Shenyang, Liaoning 110031, P.R. China
Published online on: October 18, 2018 https://doi.org/10.3892/ol.2018.9594
Pages: 73-78

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (MiR)‑506 serves a vital role in several types of cancer. However, the role of miR‑506 in bladder cancer (BCa) progression remains to be investigated. The present study demonstrated that miR‑506 expression was downregulated in BCa tissues and cell lines. Meanwhile, overexpression of miR‑506 inhibited cell proliferation, migration and invasion. Additionally, upregulated miR‑506 increased E‑cadherin, and reduced N‑cadherin and Vimentin expression levels, as markers of epithelial‑to‑mesenchymal transition. RWD domain containing 4 (RWDD4) was revealed to be a miR506 target in BCa cells, and the downregulation of RWDD4 was found to suppress BCa cell proliferation, migration and invasion. In summary, miR‑506 may suppress the aggressive properties of human BCa cells by targeting RWDD4, and thus may be a novel therapeutic target in human BCa.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK and Bellmunt J: Adjuvant chemotherapy for invasive bladder cancer: A 2013 apdated systematic review and meta-analysis of randomized trials. Eur Urol. 66:42–54. 2014. View Article : Google Scholar : PubMed/NCBI
3	Acunzo M, Romano G, Wernicke D and Croce CM: MicroRNA and cancer-A brief overview. Adv Biol Regul. 57:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
4	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
5	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
6	Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al: miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene. 34:717–725. 2015. View Article : Google Scholar : PubMed/NCBI
7	Du J, Zheng X, Cai S, Zhu Z, Tan J, Hu B, Huang Z and Jiao H: MicroRNA506 participates in pancreatic cancer pathogenesis by targeting PIM3. Mol Med Rep. 12:5121–5126. 2015. View Article : Google Scholar : PubMed/NCBI
8	Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, et al: MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 233:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
9	Arora H, Qureshi R and Park WY: miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS One. 8:e642732013. View Article : Google Scholar : PubMed/NCBI
10	Yin M, Ren X, Zhang X, Luo Y, Wang G, Huang K, Feng S, Bao X, Huang K, He X, et al: Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-kB p65 to evoke reactive oxygen species generation and p53 activation. Oncogene. 34:691–703. 2015. View Article : Google Scholar : PubMed/NCBI
11	Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P, Carrasco RA, Xiao Z, Tice DA, Higgs BW, et al: A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 31:1558–1570. 2012. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Wang X, Sun D, Tai J and Wang L: Ganoderic acid A inhibits proliferation and invasion, and promotes apoptosis in human hepatocellular carcinoma cells. Mol Med Rep. 16:3894–3900. 2017. View Article : Google Scholar : PubMed/NCBI
14	Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
15	Winter JM, Gildea DE, Andreas JP, Gatti DM, Williams KA, Lee M, Hu Y, Zhang S; NISC Comparative Sequencing Program5, ; Mullikin JC, et al: Mapping complex traits in a diversity outbred f1 mouse population identifies germline modifiers of metastasis in human prostate cancer. Cell Syst. 4:31–45 e6. 2017. View Article : Google Scholar : PubMed/NCBI
16	Enokida H, Yoshino H, Matsushita R and Nakagawa M: The role of microRNAs in bladder cancer. Investig Clin Urol. 57 Suppl 1:S60–S76. 2016. View Article : Google Scholar : PubMed/NCBI
17	Fendler A, Stephan C, Yousef GM, Kristiansen G and Jung K: The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 13:734–752. 2016. View Article : Google Scholar : PubMed/NCBI
18	Bhardwaj A, Singh S and Singh AP: MicroRNA-based cancer therapeutics: Big hope from small RNAs. Mol Cell Pharmacol. 2:213–219. 2010.PubMed/NCBI
19	Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME and Lotan Y: Bladder cancer. Nat Rev Dis Primers. 3:170222017. View Article : Google Scholar : PubMed/NCBI
20	Froehner M, Koch R, Heberling U, Novotny V, Oehlschlaeger S, Hubler M, Baretton GB, Hakenberg OW and Wirth MP: Decreased overall and bladder cancer-specific mortality with adjuvant chemotherapy after radical cystectomy: Multivariable competing risk analysis. Eur Urol. 69:984–987. 2016. View Article : Google Scholar : PubMed/NCBI
21	Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
22	Scheel C and Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin Cancer Biol. 22:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
23	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
24	Qian CN, Mei Y and Zhang J: Cancer metastasis: Issues and challenges. Chin J Cancer. 36:382017. View Article : Google Scholar : PubMed/NCBI
25	Mei Y, Yang JP and Qian CN: For robust big data analyses: A collection of 150 important pro-metastatic genes. Chin J Cancer. 36:162017. View Article : Google Scholar : PubMed/NCBI